ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Multiple Myeloma Drugs Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-37R6886
Home | Market Reports | Health| Health Conditions| Cancer
Global Multiple Myeloma Drugs Market Insights Forecast to 2028
BUY CHAPTERS

Global Multiple Myeloma Drugs Market Research Report 2025

Code: QYRE-Auto-37R6886
Report
August 2025
Pages:79
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Amgen Inc
Johnson & Johnson
Celgene
Takeda Pharmaceutical
Novartis
Daiichi Sankyo
Merck
AB Science
TEVA
PharmaMar
Johnson & Johnson

Multiple Myeloma Drugs Market Size

The global market for Multiple Myeloma Drugs was valued at US$ 935 million in the year 2024 and is projected to reach a revised size of US$ 1417 million by 2031, growing at a CAGR of 6.2% during the forecast period.

Multiple Myeloma Drugs Market

Multiple Myeloma Drugs Market

Multiple myeloma drugs fall into various drug classes, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, corticosteriods, histone deactylase inhibitors (HDACs), bisphophonates, and monoclonal antibodies (MAbs).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Multiple Myeloma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Myeloma Drugs.
The Multiple Myeloma Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Multiple Myeloma Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multiple Myeloma Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Multiple Myeloma Drugs Market Report

Report Metric Details
Report Name Multiple Myeloma Drugs Market
Accounted market size in year US$ 935 million
Forecasted market size in 2031 US$ 1417 million
CAGR 6.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Men
  • Women
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Amgen, Johnson & Johnson, Celgene, Takeda Pharmaceutical, Novartis, Daiichi Sankyo, Merck, AB Science, Teva, PharmaMar
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Multiple Myeloma Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Multiple Myeloma Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Multiple Myeloma Drugs Market growing?

Ans: The Multiple Myeloma Drugs Market witnessing a CAGR of 6.2% during the forecast period 2025-2031.

What is the Multiple Myeloma Drugs Market size in 2031?

Ans: The Multiple Myeloma Drugs Market size in 2031 will be US$ 1417 million.

Who are the main players in the Multiple Myeloma Drugs Market report?

Ans: The main players in the Multiple Myeloma Drugs Market are Amgen, Johnson & Johnson, Celgene, Takeda Pharmaceutical, Novartis, Daiichi Sankyo, Merck, AB Science, Teva, PharmaMar

What are the Application segmentation covered in the Multiple Myeloma Drugs Market report?

Ans: The Applications covered in the Multiple Myeloma Drugs Market report are Men, Women

What are the Type segmentation covered in the Multiple Myeloma Drugs Market report?

Ans: The Types covered in the Multiple Myeloma Drugs Market report are Chemotherapy, Corticosteroids, Immunomodulators, Monoclonal Antibodies, Histone Deacetylase (HDAC) Inhibitors, Proteasome Inhibitors, Others

Recommended Reports

Oncology Drug Markets

Cancer Diagnostics & Therapeutics

Immunotherapy & Antibody Drugs

1 Multiple Myeloma Drugs Market Overview
1.1 Product Definition
1.2 Multiple Myeloma Drugs by Type
1.2.1 Global Multiple Myeloma Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Chemotherapy
1.2.3 Corticosteroids
1.2.4 Immunomodulators
1.2.5 Monoclonal Antibodies
1.2.6 Histone Deacetylase (HDAC) Inhibitors
1.2.7 Proteasome Inhibitors
1.2.8 Others
1.3 Multiple Myeloma Drugs by Application
1.3.1 Global Multiple Myeloma Drugs Market Value by Application (2024 VS 2031)
1.3.2 Men
1.3.3 Women
1.4 Global Multiple Myeloma Drugs Market Size Estimates and Forecasts
1.4.1 Global Multiple Myeloma Drugs Revenue 2020-2031
1.4.2 Global Multiple Myeloma Drugs Sales 2020-2031
1.4.3 Global Multiple Myeloma Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Multiple Myeloma Drugs Market Competition by Manufacturers
2.1 Global Multiple Myeloma Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Multiple Myeloma Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Multiple Myeloma Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Multiple Myeloma Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Multiple Myeloma Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Multiple Myeloma Drugs, Product Type & Application
2.7 Global Key Manufacturers of Multiple Myeloma Drugs, Date of Enter into This Industry
2.8 Global Multiple Myeloma Drugs Market Competitive Situation and Trends
2.8.1 Global Multiple Myeloma Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Multiple Myeloma Drugs Players Market Share by Revenue
2.8.3 Global Multiple Myeloma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Multiple Myeloma Drugs Market Scenario by Region
3.1 Global Multiple Myeloma Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Multiple Myeloma Drugs Sales by Region: 2020-2031
3.2.1 Global Multiple Myeloma Drugs Sales by Region: 2020-2025
3.2.2 Global Multiple Myeloma Drugs Sales by Region: 2026-2031
3.3 Global Multiple Myeloma Drugs Revenue by Region: 2020-2031
3.3.1 Global Multiple Myeloma Drugs Revenue by Region: 2020-2025
3.3.2 Global Multiple Myeloma Drugs Revenue by Region: 2026-2031
3.4 North America Multiple Myeloma Drugs Market Facts & Figures by Country
3.4.1 North America Multiple Myeloma Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Multiple Myeloma Drugs Sales by Country (2020-2031)
3.4.3 North America Multiple Myeloma Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Multiple Myeloma Drugs Market Facts & Figures by Country
3.5.1 Europe Multiple Myeloma Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Multiple Myeloma Drugs Sales by Country (2020-2031)
3.5.3 Europe Multiple Myeloma Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Multiple Myeloma Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Multiple Myeloma Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Multiple Myeloma Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Multiple Myeloma Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Multiple Myeloma Drugs Market Facts & Figures by Country
3.7.1 Latin America Multiple Myeloma Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Multiple Myeloma Drugs Sales by Country (2020-2031)
3.7.3 Latin America Multiple Myeloma Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Multiple Myeloma Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Multiple Myeloma Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Multiple Myeloma Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Multiple Myeloma Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Multiple Myeloma Drugs Sales by Type (2020-2031)
4.1.1 Global Multiple Myeloma Drugs Sales by Type (2020-2025)
4.1.2 Global Multiple Myeloma Drugs Sales by Type (2026-2031)
4.1.3 Global Multiple Myeloma Drugs Sales Market Share by Type (2020-2031)
4.2 Global Multiple Myeloma Drugs Revenue by Type (2020-2031)
4.2.1 Global Multiple Myeloma Drugs Revenue by Type (2020-2025)
4.2.2 Global Multiple Myeloma Drugs Revenue by Type (2026-2031)
4.2.3 Global Multiple Myeloma Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Multiple Myeloma Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Multiple Myeloma Drugs Sales by Application (2020-2031)
5.1.1 Global Multiple Myeloma Drugs Sales by Application (2020-2025)
5.1.2 Global Multiple Myeloma Drugs Sales by Application (2026-2031)
5.1.3 Global Multiple Myeloma Drugs Sales Market Share by Application (2020-2031)
5.2 Global Multiple Myeloma Drugs Revenue by Application (2020-2031)
5.2.1 Global Multiple Myeloma Drugs Revenue by Application (2020-2025)
5.2.2 Global Multiple Myeloma Drugs Revenue by Application (2026-2031)
5.2.3 Global Multiple Myeloma Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Multiple Myeloma Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Company Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Amgen Multiple Myeloma Drugs Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Company Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Johnson & Johnson Multiple Myeloma Drugs Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Celgene
6.3.1 Celgene Company Information
6.3.2 Celgene Description and Business Overview
6.3.3 Celgene Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Celgene Multiple Myeloma Drugs Product Portfolio
6.3.5 Celgene Recent Developments/Updates
6.4 Takeda Pharmaceutical
6.4.1 Takeda Pharmaceutical Company Information
6.4.2 Takeda Pharmaceutical Description and Business Overview
6.4.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolio
6.4.5 Takeda Pharmaceutical Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Company Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Novartis Multiple Myeloma Drugs Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Daiichi Sankyo
6.6.1 Daiichi Sankyo Company Information
6.6.2 Daiichi Sankyo Description and Business Overview
6.6.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Daiichi Sankyo Multiple Myeloma Drugs Product Portfolio
6.6.5 Daiichi Sankyo Recent Developments/Updates
6.7 Merck
6.7.1 Merck Company Information
6.7.2 Merck Description and Business Overview
6.7.3 Merck Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Merck Multiple Myeloma Drugs Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 AB Science
6.8.1 AB Science Company Information
6.8.2 AB Science Description and Business Overview
6.8.3 AB Science Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 AB Science Multiple Myeloma Drugs Product Portfolio
6.8.5 AB Science Recent Developments/Updates
6.9 Teva
6.9.1 Teva Company Information
6.9.2 Teva Description and Business Overview
6.9.3 Teva Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Teva Multiple Myeloma Drugs Product Portfolio
6.9.5 Teva Recent Developments/Updates
6.10 PharmaMar
6.10.1 PharmaMar Company Information
6.10.2 PharmaMar Description and Business Overview
6.10.3 PharmaMar Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 PharmaMar Multiple Myeloma Drugs Product Portfolio
6.10.5 PharmaMar Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Multiple Myeloma Drugs Industry Chain Analysis
7.2 Multiple Myeloma Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Multiple Myeloma Drugs Production Mode & Process Analysis
7.4 Multiple Myeloma Drugs Sales and Marketing
7.4.1 Multiple Myeloma Drugs Sales Channels
7.4.2 Multiple Myeloma Drugs Distributors
7.5 Multiple Myeloma Drugs Customer Analysis
8 Multiple Myeloma Drugs Market Dynamics
8.1 Multiple Myeloma Drugs Industry Trends
8.2 Multiple Myeloma Drugs Market Drivers
8.3 Multiple Myeloma Drugs Market Challenges
8.4 Multiple Myeloma Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Amgen Inc
Johnson & Johnson
Celgene
Takeda Pharmaceutical
Novartis
Daiichi Sankyo
Merck
AB Science
TEVA
PharmaMar
Johnson & Johnson
List of Tables
 Table 1. Global Multiple Myeloma Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Multiple Myeloma Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Multiple Myeloma Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Multiple Myeloma Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Multiple Myeloma Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Multiple Myeloma Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Multiple Myeloma Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Multiple Myeloma Drugs Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Multiple Myeloma Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Multiple Myeloma Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Multiple Myeloma Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Multiple Myeloma Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Multiple Myeloma Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Myeloma Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Multiple Myeloma Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Multiple Myeloma Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Multiple Myeloma Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Multiple Myeloma Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Multiple Myeloma Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Multiple Myeloma Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Multiple Myeloma Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Multiple Myeloma Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Multiple Myeloma Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Multiple Myeloma Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Multiple Myeloma Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Multiple Myeloma Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Multiple Myeloma Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Multiple Myeloma Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Multiple Myeloma Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Multiple Myeloma Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Multiple Myeloma Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Multiple Myeloma Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Multiple Myeloma Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Multiple Myeloma Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Multiple Myeloma Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Multiple Myeloma Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Multiple Myeloma Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Multiple Myeloma Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Multiple Myeloma Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Multiple Myeloma Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Multiple Myeloma Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Multiple Myeloma Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Multiple Myeloma Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Multiple Myeloma Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Multiple Myeloma Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Multiple Myeloma Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Multiple Myeloma Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Multiple Myeloma Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Multiple Myeloma Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Multiple Myeloma Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Multiple Myeloma Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Multiple Myeloma Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Multiple Myeloma Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Multiple Myeloma Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Multiple Myeloma Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Multiple Myeloma Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Multiple Myeloma Drugs Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Multiple Myeloma Drugs Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Multiple Myeloma Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Multiple Myeloma Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Multiple Myeloma Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Multiple Myeloma Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Multiple Myeloma Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Multiple Myeloma Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Multiple Myeloma Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Multiple Myeloma Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Multiple Myeloma Drugs Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Multiple Myeloma Drugs Price (USD/Unit) by Application (2026-2031)
 Table 70. Amgen Company Information
 Table 71. Amgen Description and Business Overview
 Table 72. Amgen Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Amgen Multiple Myeloma Drugs Product
 Table 74. Amgen Recent Developments/Updates
 Table 75. Johnson & Johnson Company Information
 Table 76. Johnson & Johnson Description and Business Overview
 Table 77. Johnson & Johnson Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Johnson & Johnson Multiple Myeloma Drugs Product
 Table 79. Johnson & Johnson Recent Developments/Updates
 Table 80. Celgene Company Information
 Table 81. Celgene Description and Business Overview
 Table 82. Celgene Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Celgene Multiple Myeloma Drugs Product
 Table 84. Celgene Recent Developments/Updates
 Table 85. Takeda Pharmaceutical Company Information
 Table 86. Takeda Pharmaceutical Description and Business Overview
 Table 87. Takeda Pharmaceutical Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Takeda Pharmaceutical Multiple Myeloma Drugs Product
 Table 89. Takeda Pharmaceutical Recent Developments/Updates
 Table 90. Novartis Company Information
 Table 91. Novartis Description and Business Overview
 Table 92. Novartis Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Novartis Multiple Myeloma Drugs Product
 Table 94. Novartis Recent Developments/Updates
 Table 95. Daiichi Sankyo Company Information
 Table 96. Daiichi Sankyo Description and Business Overview
 Table 97. Daiichi Sankyo Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. Daiichi Sankyo Multiple Myeloma Drugs Product
 Table 99. Daiichi Sankyo Recent Developments/Updates
 Table 100. Merck Company Information
 Table 101. Merck Description and Business Overview
 Table 102. Merck Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Merck Multiple Myeloma Drugs Product
 Table 104. Merck Recent Developments/Updates
 Table 105. AB Science Company Information
 Table 106. AB Science Description and Business Overview
 Table 107. AB Science Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. AB Science Multiple Myeloma Drugs Product
 Table 109. AB Science Recent Developments/Updates
 Table 110. Teva Company Information
 Table 111. Teva Description and Business Overview
 Table 112. Teva Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. Teva Multiple Myeloma Drugs Product
 Table 114. Teva Recent Developments/Updates
 Table 115. PharmaMar Company Information
 Table 116. PharmaMar Description and Business Overview
 Table 117. PharmaMar Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 118. PharmaMar Multiple Myeloma Drugs Product
 Table 119. PharmaMar Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Multiple Myeloma Drugs Distributors List
 Table 123. Multiple Myeloma Drugs Customers List
 Table 124. Multiple Myeloma Drugs Market Trends
 Table 125. Multiple Myeloma Drugs Market Drivers
 Table 126. Multiple Myeloma Drugs Market Challenges
 Table 127. Multiple Myeloma Drugs Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Multiple Myeloma Drugs
 Figure 2. Global Multiple Myeloma Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Multiple Myeloma Drugs Market Share by Type: 2024 & 2031
 Figure 4. Chemotherapy Product Picture
 Figure 5. Corticosteroids Product Picture
 Figure 6. Immunomodulators Product Picture
 Figure 7. Monoclonal Antibodies Product Picture
 Figure 8. Histone Deacetylase (HDAC) Inhibitors Product Picture
 Figure 9. Proteasome Inhibitors Product Picture
 Figure 10. Others Product Picture
 Figure 11. Global Multiple Myeloma Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 12. Global Multiple Myeloma Drugs Market Share by Application: 2024 & 2031
 Figure 13. Men
 Figure 14. Women
 Figure 15. Global Multiple Myeloma Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Multiple Myeloma Drugs Market Size (2020-2031) & (US$ Million)
 Figure 17. Global Multiple Myeloma Drugs Sales (2020-2031) & (K Units)
 Figure 18. Global Multiple Myeloma Drugs Average Price (USD/Unit) & (2020-2031)
 Figure 19. Multiple Myeloma Drugs Report Years Considered
 Figure 20. Multiple Myeloma Drugs Sales Share by Manufacturers in 2024
 Figure 21. Global Multiple Myeloma Drugs Revenue Share by Manufacturers in 2024
 Figure 22. Global 5 and 10 Largest Multiple Myeloma Drugs Players: Market Share by Revenue in Multiple Myeloma Drugs in 2024
 Figure 23. Multiple Myeloma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Global Multiple Myeloma Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 25. North America Multiple Myeloma Drugs Sales Market Share by Country (2020-2031)
 Figure 26. North America Multiple Myeloma Drugs Revenue Market Share by Country (2020-2031)
 Figure 27. U.S. Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Canada Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Europe Multiple Myeloma Drugs Sales Market Share by Country (2020-2031)
 Figure 30. Europe Multiple Myeloma Drugs Revenue Market Share by Country (2020-2031)
 Figure 31. Germany Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. France Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. U.K. Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Italy Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Russia Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Asia Pacific Multiple Myeloma Drugs Sales Market Share by Region (2020-2031)
 Figure 37. Asia Pacific Multiple Myeloma Drugs Revenue Market Share by Region (2020-2031)
 Figure 38. China Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Japan Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. South Korea Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. India Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Australia Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Taiwan Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Indonesia Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Thailand Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Malaysia Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Philippines Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Latin America Multiple Myeloma Drugs Sales Market Share by Country (2020-2031)
 Figure 49. Latin America Multiple Myeloma Drugs Revenue Market Share by Country (2020-2031)
 Figure 50. Mexico Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Brazil Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Argentina Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Middle East and Africa Multiple Myeloma Drugs Sales Market Share by Country (2020-2031)
 Figure 54. Middle East and Africa Multiple Myeloma Drugs Revenue Market Share by Country (2020-2031)
 Figure 55. Turkey Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Saudi Arabia Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. UAE Multiple Myeloma Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Global Sales Market Share of Multiple Myeloma Drugs by Type (2020-2031)
 Figure 59. Global Revenue Market Share of Multiple Myeloma Drugs by Type (2020-2031)
 Figure 60. Global Multiple Myeloma Drugs Price (USD/Unit) by Type (2020-2031)
 Figure 61. Global Sales Market Share of Multiple Myeloma Drugs by Application (2020-2031)
 Figure 62. Global Revenue Market Share of Multiple Myeloma Drugs by Application (2020-2031)
 Figure 63. Global Multiple Myeloma Drugs Price (USD/Unit) by Application (2020-2031)
 Figure 64. Multiple Myeloma Drugs Value Chain
 Figure 65. Channels of Distribution (Direct Vs Distribution)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Lenalidomide Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Drugs for Multiple Myeloma Market Research Report 2024
Multiple Myeloma Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global ImmunOthersapy Drugs for Multiple Myeloma Market Research Report 2024
Global Proteasome Inhibitors for Multiple Myeloma Market Research Report 2024
Revlimid Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Monoclonal Antibody for Multiple Myeloma Market Research Report 2024
Revlimid Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Immunomodulator for Multiple Myeloma Market Research Report 2024
Global Traditional ChemOthersapy Drugs for Multiple Myeloma Market Research Report 2024
Refractory Multiple Myeloma Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Multiple Myeloma Treatment Market Research Report 2024
Thalomid Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hematological Malignancy Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Small Molecule Inhibitors for Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Lenalidomide API Market Research Report 2024
Monoclonal Antibody Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Peptide Therapeutics Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Therapeutic Monoclonal Antibodies Drug Market Research Report 2024
Global Monoclonal Antibody Drugs for Cancer Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions